COLLABORATIVE RESEARCH & DEVELOPMENT AND COMMERCIAL RIGHTS AGREEMENTDevelopment and Commercial Rights Agreement • May 9th, 2014 • Agenus Inc • Biological products, (no disgnostic substances) • England and Wales
THIS COLLABORATIVE RESEARCH & DEVELOPMENT AND COMMERCIAL RIGHTS AGREEMENT (this “AGREEMENT”) is made the 21st day of December, 2012 (“EFFECTIVE DATE”) by and between RECEPTA BIOPHARMA S.A. with its principal place of business at Rua Tabapuã 1123, cj 36, Sao Paulo, SP Brazil, enrolled with the CNPJ/MF under No. CNPJ/MF: 07.896.151/0001-19, with its By-laws duly filed with the Commercial Registry of the State of São Paulo – JUCESP under NIRE 35.300.329.287 (“RECEPTA”), the LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, a Swiss not- for-profit corporation, with its registered office at Stadelhoferstrasse 22, 8001, Zurich, Switzerland, and having an office at 666 Third Avenue, New York, NY 10017, United States of America (“LICR”), and 4-ANTIBODY AG (“4AB”), incorporated in Switzerland with its registered office at Hochbergerstrasse 60C, CH-4057 Basel, Switzerland. RECEPTA, LICR, and 4AB may each be referred to herein, individually, as a “PARTY” or, collectively, as the “PARTIES”.
